Brochure More information from http://www.researchandmarkets.com/reports/3128342/ Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Description: Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-tnfs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-tnfs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch. Originally developed as a cancer therapy, MTX has become the leading DMARD in most countries because of its rapid onset of action and low cost. MTX is an antineoplastic antimetabolite with immunosuppressant actions. Its use for the treatment of RA began in the 1970s, as it had been shown to sustain benefits for at least 50% of RA patients. MTX is an antagonist of folic acid metabolism, and its effects in inflammatory diseases may be secondary to the induction of adenosine release and the inhibition of polyamines. Scope - Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Methotrexate including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Methotrexate for the top 10 countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China and India. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return. - Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential. - Make more informed business decisions from insightful and in-depth analysis of Methotrexate performance. - Obtain sales forecast for Methotrexate from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India). Contents: 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 2.3 Upcoming Related Reports 3 Disease Overview 3.1 Etiology and Pathophysiology 3.1.1 Etiology 3.1.2 Pathophysiology 3.2 Symptoms 3.3 Prognosis
3.4 Quality of Life 4 Disease Management 4.1 Diagnosis and Treatment Overview 4.1.1 Diagnosis 4.1.2 Treatment Guidelines 4.1.3 Leading Prescribed Drugs for the Treatment of RA 4.1.4 Clinical Practice 5 Competitive Assessment 5.1 Overview 6 Methotrexate (Numerous Brands) 6.1 Overview 6.2 Efficacy 6.3 Safety 6.4 SWOT Analysis 6.5 Forecast 7 Appendix 7.1 Bibliography 7.2 Abbreviations 7.3 Methodology 7.4 Forecasting Methodology 7.4.1 Diagnosed RA Patients 7.4.2 Percentage of Drug-Treated Patients 7.4.3 General Pricing Assumptions 7.4.4 Individual Drug Assumptions 7.4.5 Generic and Biosimilar Erosion 7.5 Primary Research - KOLs Interviewed for This Report 7.6 Primary Research - Prescriber Survey 7.7 About the Authors 7.7.1 Analyst 7.7.2 Reviewer 7.7.3 Therapy Area Director 7.7.4 Global Head of Healthcare 7.8 About Us 7.9 Disclaimer 1.1 List of Tables Table 1: Symptoms of RA Table 2: 1987 ACR Diagnostic Criteria for RA Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity Table 6: EULAR 2013 Criteria for RA Remission Table 7: Most Prescribed Biologics for RA (After csdmards) in the Global Markets, 2014 Table 8: Leading Branded Treatments for RA 2014 Table 9: Product Profile - MTX Table 10: MTX SWOT Analysis, 2014 Table 11: Global Sales Forecasts ($m) for MTX, 2013-2023 Table 12: High-Prescribing Physicians (non-kols) Surveyed, By Country 1.2 List of Figures Figure 1: Normal Synovial Joint and Synovial Joint with RA Figure 2: Cellular and Cytokine Targets for the Current RA Drugs Figure 3: Disease Management Flowchart for Early RA - ACR 2012 Figure 4: Disease Management Flowchart for Established RA - ACR 2012 Figure 5: Flowchart for the Management of RA - EULAR 2013 Ordering: Order Online - http://www.researchandmarkets.com/reports/3128342/ Order by Fax - using the form below Order by Post - print the order form below and send to
Research and Markets, Guinness Centre, Taylors Lane, Dublin 8,
Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/ Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Web Address: Office Code: Product Formats Please select the product formats and quantity you require: http://www.researchandmarkets.com/reports/3128342/ SCF7LHSC Single User: Site License: Enterprisewide: Quantity USD 3495 USD 6990 USD 10485 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Pay by wire transfer: Please transfer funds to: Account number 833 130 83 Sort code 98-53-30 Swift code IBAN number Bank Address ULSBIE2D IE78ULSB98533083313083 Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World